סך הכנסות החברה Capricor Therapeutics, Inc. (CAPR)

Capricor Therapeutics (CAPR) gross sales revenue dynamics on the GURU.Markets chart demonstrate growth driven by preparations for the commercialization of Duchenne muscular dystrophy therapy. This metric equals 0.00. Stability is ensured by contracts with external manufacturing plants to scale drug production, while business development relies on a team of scientists motivated by the treatment of severe cardiac pathologies and competitive compensation.

Capricor Therapeutics revenues depend on the commercial implementation of cell technologies for the therapy of Duchenne muscular dystrophy. By analyzing the company's sales statistics, an investor can see the dynamics of actual cash inflows from sales. This indicator separates the long-term fundamental trend from market noise, capturing the compression of multiples. The metric measures the efficiency of monetizing innovations in an environment of expensive borrowing. Steady growth of this indicator confirms the viability of the business model and reduces the risk of capital freeze.